Has anyone tried sell you peptides yet? If not, they probably will soon. Peptides, once a niche interest for bodybuilders and biohackers, are an increasingly popular class of substance that is being looked at fashionably by fringe influencers and the current U.S. Secretary of Health and Human Services.
Earlier this year, Robert F. Kennedy Jr. told podcaster Joe Rogan that the government intends to loosen restrictions on peptide production. This week, it could finally happen: On July 23 and 24, the Food and Drug Administration will debate the possibility of reclassifying the peptide class so that pharmacies can legally make custom compounds through a process known as compounding. The move would reverse a decision made in 2023 by the Biden administration that banned the combining of certain peptides.
Although scientists working at the agency have recommended against himmultiple industry insiders tell WIRED they believe the FDA will approve the reclassification anyway because the committee has met to review contains peptide boosters. Some players in the telehealth world are already operating under the assumption that the floodgates will open soon. “We’re getting everything ready,” says Myra Ahmad, chief executive of telehealth platform Mochi Health, which originally focused on GLP-1 drugs. “We have pharmacies that have done all the safety testing and set the prices.”
Some of the largest telehealth companies have been waiting for this moment for over a year. Virtual healthcare giant Hims & Hers Health bought the peptide manufacturing facility in February 2025 and is currently developing clinical protocols for the peptides, according to its chief medical officer Anant Vinjamoori, who is scheduled to testify before the head of the FDA. Joshua Fritzler, president of pharmacy Olympia Pharmaceuticals, says the company has been preparing ahead of time for the anticipated changes by “spending a lot of money to create these formulas” to be ready if the FDA gives the green delicate.
“There is an awareness in the industry that something big is happening,” he says.
The GLP-1 boom has sold people on the idea of injecting drugs at home and has proven to be a cash cow for pharmacies and virtual clinics. Now, however, many of these companies want to expand their horizons. Cole Thomas, director of sales and operations for pharmacy marketing and technology platform RxConnexion, says some of the company’s pharmaceutical clients are already testing peptides that are likely to be popular. One of these varieties, BPC-157it is advertised as a medicinal compound and is half of a combination known as the “Wolverine stack.” (BPC stands for “Body Protection Compound”).
Cameron Bravo, a scientist at the biotechnology company Sapho Bio, says his company has also been approached about testing various peptides. (The client is Mochi Health.) Sapho Bio performs tests to “verify” the formulas brought in by customers, ensuring that the blends are free of contaminants and properly sealed. So far, BPC-157 has been tested, as well as more undiscovered products such as MOTS-c, which evangelists tout as “exercise in a vial.” Some pharmacies the company cooperates with already test many products, which involves significant costs. “They probably have about $100,000 invested in them before they run out completely,” he says.
Even if this week’s meeting goes exactly as peptide booster manufacturers want, and the committee approves all the substances up for discussion, it won’t immediately give a green delicate to sellers. The next step includes a review period during which the FDA will propose rules and the public can comment. “It’s a long process,” says Gerard Olson, who most recently served as director of research at LegitScript, a company that certifies telehealth providers and pharmacies.